NorthRock Partners LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

NorthRock Partners LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 874 shares of the biopharmaceutical company’s stock after purchasing an additional 166 shares during the period. NorthRock Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $459,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. boosted its position in Regeneron Pharmaceuticals by 22.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 2,169 shares of the biopharmaceutical company’s stock worth $1,139,000 after purchasing an additional 398 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,761 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 146 shares during the period. MGO One Seven LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 28.1% in the second quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 106 shares during the last quarter. GW Henssler & Associates Ltd. grew its position in Regeneron Pharmaceuticals by 5.5% during the second quarter. GW Henssler & Associates Ltd. now owns 21,482 shares of the biopharmaceutical company’s stock valued at $11,278,000 after buying an additional 1,122 shares during the period. Finally, Meritage Portfolio Management purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $6,014,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Finally, Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $817.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $576.42 on Thursday. The stock has a 50-day moving average price of $574.15 and a 200 day moving average price of $563.61. The stock has a market capitalization of $61.09 billion, a P/E ratio of 14.53, a P/E/G ratio of 1.84 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,020.55. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the prior year, the company posted $11.56 EPS. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.